By: Stock Whisper 11/25/13
Article :Celldex Will Not Stop Here
The positive trial data of ReACT study is an encouraging event in the therapeutic area of recurring glioblastoma. Currently, there are limited treatment options available for the indication, with the patients having very low survival rates. If and when the vaccine is approved it could provide a breakthrough for not only Celldex but also for immunotherapy. Additionally, the Genentech's vaccine Avastin was approved on accelerated basis because of its objective response rates. If the response rates of rindopepimut reported continue in the final data the vaccine may also be approved on an accelerated basis, owing to absence of viable treatment for glioblastoma patients.
The share prices of the company are currently witnessing an upward momentum and are expected to continue the trend. The company is expected to release data for its experimental drug CDX-1135 for dense deposit disease, in February 2014 conference call. Furthermore, the study CDX-301 for hematopoietic stem cell transplant (HSCT) is also expected to initiate in early 2014.
The company holds promise and the investor sentiment is also positive and is expected to reach it mean price target of $36.89 over the next few months. The analyst recommendation is a Buy. Overall, the stock is a sound investment and has major potential over the long run.
and more articles coming.
Stock Market & Financial Investment News
November 24, 2013
15:06 EDT CLDX Celldex reports data on ongoing exploratory Phase 2 ReACT study of rindopepimut
Celldex Therapeutics reported interim data from its ongoing, exploratory Phase 2 ReACT study of rindopepimut in recurrent glioblastoma. Rindopepimut is an immunotherapeutic vaccine that targets the tumor specific oncogene EGFRvIII(v3). Patients with EGFRvIII-positive glioblastoma typically have a worse prognosis than the overall glioblastoma population, including poor long term survival. The ReACT results demonstrate promising signs of clinical activity in advanced patient populations, including patients both naïve and refractory to bevacizumab, Avastin. An update on long-term survival for the three completed Phase 2 frontline studies in EGFRvIII-positive glioblastoma was also presented and results continue to exceed outcomes seen in contemporary controls."Patients who have grown right though Avastin are resistant to all of our available therapies," said David Reardon, M.D. "The potent immune response generated by rindopepimut and preliminary signs of anti-tumor activity in the Avastin refractory patients in the ReACT study are very exciting. The additional signal of an improved survival outcome in Avastin naïve patients further supports the potential activity of rindopepimut. I look forward to the final results of this study and hope they confirm what we have seen so far."
Here's DD For Data Coming Out.
Keep Your Eyes on Celldex
By Keith Speights | More Articles
November 11, 2013 | Comments (0)
Investors are also intensely interested in results related to Celldex's lead drug, Rindopepimut. The company is scheduled to discuss data from a phase 2 study of its cancer vaccine in combination with Roche's Avastinat the World Federation of Neuro-Oncology meeting on Nov. 24. A phase 3 study ofRindopepimut is also under way in combination with Merck's Temodar in treating EGFRv3-positive glioblastoma
As previously disclosed, Celldex will issue a press release in concordance with the presentation on November 24 and will host a conference call to review the data on Monday, November 25 at 8:30 am ET.
Why Facebook is Better Than Twitter
BY Chris Ciaccia | 11/20/13 -
Analyst Rating Network 11/20/13 Facebook ( FB )
11/15/2013 Zacks Reiterated Rating Facebook Inc. (FB) Outperform Outperform $59.00